Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niclosamide in patients with COVID-19
NCT04542434Phase 2Withdrawn
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Niclosamide with Placebo (2 arms). Primary endpoints: Mortality at 6 weeks, Treatment Emergent Adverse Events at 6 weeks and 8 more. Planned start Jan 2022; status: withdrawn.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04542434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542434.